We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Randox and Bosch Partner to Launch Molecular Diagnostics Platform

By LabMedica International staff writers
Posted on 01 Mar 2018
Global healthcare diagnostics manufacturer Randox Laboratories (Crumlin, Northern Ireland, UK) has partnered with Bosch Healthcare Solutions GmbH (Waiblingen, Germany) to launch Vivalytic, an all-in-one fully automated solution for molecular diagnostics.

Randox develops, manufactures and markets diagnostic reagents and equipment for laboratory medicine. More...
Its range of products includes Biochip Array Technology, clinical chemistry analyzers and reagents, quality control materials and schemes and an extensive life science portfolio. The company’s products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories.

Bosch Healthcare Solutions GmbH, a wholly owned subsidiary of Robert Bosch GmbH, develops products and services to improve people’s health and quality of life. The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.

Vivalytic combines the broadest range of test options and uses Randox-patented Biochip Array Technology, making it the easiest to use and most comprehensive multiplex PCR platform in the market. The device also supports single-plex and low-plex testing, simplifying the processes for otherwise complex laboratory test procedures. Depending upon the test application, Vivalytic delivers results from 30 minutes.

The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually transmitted infections. The Respiratory Multiplex Array simultaneously detects 22 viral and bacterial pathogens, including Bordetella parapertussis, without the need for secondary or confirmatory testing to inform clinical treatment decisions. The STI array enables the detection of 10 viral, bacterial and protozoan STIs from a single urine or urogenital swab sample.

“This is transformational for patients and doctors; never before has there been this level of accessibility to such a wealth of molecular tests. Randox molecular assays continue to evolve, keeping precise diagnostics for targeted patient therapy at the centre. With Vivalytic, there’s no limit to the testing portfolio that can be made available on its universal platform, and importantly it delivers results quickly and accurately,” said Dr Peter FitzGerald, MD of Randox Laboratories.

“This is an ideal partnership for Randox, combining our expertise in molecular laboratory diagnostics with Bosch’s cutting-edge engineering. With antibiotic resistance one of the most pressing public health issues faced across the world today, we’re delighted that the first tests available on Vivalytic are our industry-leading multiplex panels for respiratory and sexually transmitted infections. This Randox-Bosch partnership enables quick, accurate diagnosis, improved patient care and the effective stewardship of critical medicines.”

“We are enthusiastic about having gained Randox as the first partner on our platform with two initial panels available from the start. It´s the beginning of jointly expanding the Vivalytic test portfolio for our clients,” said Marc Meier, General Manager of Bosch Healthcare Solutions. “In this partnership the core competencies of Bosch in automation, miniaturization, and networking are complemented by Randox’s expertise in developing and commercializing innovative diagnostic solutions.”


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i1000
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.